EP Patent

EP3658156A1 — Methods of treating myelodysplastic syndrome

Assigned to Geron Corp · Expires 2020-06-03 · 6y expired

What this patent protects

The present invention provides methods of treating a myelodysplastic syndrome (MDS) in a subject who is naive in terms of treatment with an agent selected from a hypomethylation agent (HMA) and lenalidomide, or both. The method comprises administering to an effective amount of a …

USPTO Abstract

The present invention provides methods of treating a myelodysplastic syndrome (MDS) in a subject who is naive in terms of treatment with an agent selected from a hypomethylation agent (HMA) and lenalidomide, or both. The method comprises administering to an effective amount of a telomerase inhibitor, such as, for example, imetelstat or imetelstat sodium. In some cases, the treated subject is classified as low or intermediate IPSS risk MDS 1 and / or is relapsed of MDS / is refractory to the erythropoietin stimulating agent (ESA).

Drugs covered by this patent

Patent Metadata

Patent number
EP3658156A1
Jurisdiction
EP
Classification
—
Expires
2020-06-03
Drug substance claim
No
Drug product claim
No
Assignee
Geron Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.